Recent Advances in Targeting Human Mitochondrial AAA+ Proteases to Develop Novel Cancer Therapeutics

2019 ◽  
pp. 119-142 ◽  
Author(s):  
Keith S. Wong ◽  
Walid A. Houry
Keyword(s):  
Cancer Therapeutics ◽  
Recent Advances

Inhibitors of Cell Cycle Kinases: Recent Advances and Future Prospects as Cancer Therapeutics

2012 ◽  
Vol 17 (2) ◽  
pp. 175-198 ◽  
Author(s):  
Andrew Stone ◽  
Robert L. Sutherland ◽  
Elizabeth A . Musgrove
Keyword(s):  
Cell Cycle ◽  
Cancer Therapeutics ◽  
Future Prospects ◽  
Recent Advances

Recent advances in liposome formulations for breast cancer therapeutics

2021 ◽  
Author(s):  
Biyao Yang ◽  
Bo-ping Song ◽  
Shaina Shankar ◽  
Anna Guller ◽  
Wei Deng
Keyword(s):  
Breast Cancer ◽  
Cancer Therapeutics ◽  
Recent Advances

Recent Advances in Gelatin-Based Nanomedicine for Targeted Delivery of Anti-Cancer Drugs

2021 ◽  
Vol 27 ◽  
Author(s):  
Faisal Raza ◽  
Liu Siyu ◽  
Hajra Zafar ◽  
Zul Kamal ◽  
Bo Zheng ◽  
...  
Keyword(s):  
Cancer Therapy ◽  
Targeted Delivery ◽  
Cancer Therapeutics ◽  
Natural Polymers ◽  
Gelatin Nanoparticles ◽  
Good Surface ◽  
Recent Advances ◽  
Wide Range ◽  
Anti Cancer ◽  
Cancer Nanomedicine

: Nanoparticles based on natural polymers are utilized for the development of a wide range of drug delivery systems (DDS) in the current era. Gelatin-based nanoparticles, for example, are a remarkable cancer therapy with high efficacy and specificity. This paper reviews the recent advancements in gelatin-based nanomedicine for use in cancer therapeutics. Due to the characteristics features of gelatin, such as biocompatibility, biodegradability, stability, and good surface properties, these nanoparticles provide high therapeutic potency in cancer nanomedicine. The surface of gelatin can be modified in a number of ways using various ligands to explore the platform for the development of a more novel DDS. Various methods are available for the preparation of gelatin nanomedicine discussed in this review. In addition, various cross-linkers to stabilized nanocarriers and stimuli base gelatin nanoparticles are reviewed. Furthermore, recent advances and research in gelatin-based nanomedicine are discussed. Also, some drawbacks and challenges are evaluated. In general, this paper paves the pathway to identify the details about the gelatin-based DDS for cancer therapy.

Recent Advances in Cancer Therapeutics

2015 ◽  
pp. 1-63 ◽  
Author(s):  
Nicola Chessum ◽  
Keith Jones ◽  
Elisa Pasqua ◽  
Michael Tucker
Keyword(s):  
Cancer Therapeutics ◽  
Recent Advances

Recent advances in nanoparticles-based strategies for cancer therapeutics and antibacterial applications

2019 ◽  
pp. 255-293 ◽  
Author(s):  
Surendra Gulla ◽  
Dakshayani Lomada ◽  
Vadali V.S.S. Srikanth ◽  
Muthukonda Venkatakrishnan Shankar ◽  
Kakarla Raghava Reddy ◽  
...  
Keyword(s):  
Cancer Therapeutics ◽  
Recent Advances

scholarly journals Going with the Flow: Modeling the Tumor Microenvironment Using Microfluidic Technology

Cancers ◽  
2021 ◽  
Vol 13 (23) ◽  
pp. 6052
Author(s):  
Hongyan Xie ◽  
Jackson W. Appelt ◽  
Russell W. Jenkins
Keyword(s):  
Tumor Microenvironment ◽  
Acquired Resistance ◽  
Cancer Therapeutics ◽  
Cell Types ◽  
Model Systems ◽  
Host Immune System ◽  
Cancer Therapies ◽  
Extrinsic Factors ◽  
Recent Advances ◽  
Microfluidic Technology

Recent advances in cancer immunotherapy have led a paradigm shift in the treatment of multiple malignancies with renewed focus on the host immune system and tumor–immune dynamics. However, intrinsic and acquired resistance to immunotherapy limits patient benefits and wider application. Investigations into the mechanisms of response and resistance to immunotherapy have demonstrated key tumor-intrinsic and tumor-extrinsic factors. Studying complex interactions with multiple cell types is necessary to understand the mechanisms of response and resistance to cancer therapies. The lack of model systems that faithfully recapitulate key features of the tumor microenvironment (TME) remains a challenge for cancer researchers. Here, we review recent advances in TME models focusing on the use of microfluidic technology to study and model the TME, including the application of microfluidic technologies to study tumor–immune dynamics and response to cancer therapeutics. We also discuss the limitations of current systems and suggest future directions to utilize this technology to its highest potential.

Recent Advances in Strategies for Extracellular Matrix Degradation and Synthesis Inhibition for Improved Therapy of Solid Tumors

2020 ◽  
Vol 26 (42) ◽  
pp. 5456-5467
Author(s):  
Kamalpreet Kaur Sandha ◽  
Monu Kumar Shukla ◽  
Prem N. Gupta
Keyword(s):  
Extracellular Matrix ◽  
Solid Tumors ◽  
Solid Tumor ◽  
Drug Exposure ◽  
Tumor Tissue ◽  
Fluid Pressure ◽  
Cancer Therapeutics ◽  
Recent Advances ◽  
Extracellular Matrix Components ◽  
Potential Area

Despite a great deal of efforts made by researchers and the advances in the technology, the treatment of cancer is very challenging. Significant advances in the field of cancer therapeutics have been made but due to the complexity of solid tumor microenvironment, specially their dense extracellular matrix (which makes the conditions favorable for cancer growth, metastasis and acts as a barrier to the chemotherapeutic drugs as well as nanomedicine), the treatment of solid tumors is difficult. Overexpression of extracellular matrix components such as collagen, hyaluronan and proteoglycans in solid tumor leads to high interstitial fluid pressure, hypoxia, vascular collapse and poor perfusion which hinder the diffusion and convection of the drugs into the tumor tissue. This leads to the emergence of drug resistance and poor antitumor efficacy of chemotherapeutics. A number of approaches are being investigated in order to modulate this barrier for improved outcome of cancer chemotherapy. In this review, recent advances in the various approaches for the modulation of the extracellular matrix barrier of the solid tumor are covered and significant findings are discussed in an attempt to facilitate more investigations in this potential area to normalize the tumor extracellular matrix for improving drug exposure to solid tumor.

scholarly journals Ribosomal proteins and human diseases: molecular mechanisms and targeted therapy

2021 ◽  
Vol 6 (1) ◽  
Author(s):  
Jian Kang ◽  
Natalie Brajanovski ◽  
Keefe T. Chan ◽  
Jiachen Xuan ◽  
Richard B. Pearson ◽  
...  
Keyword(s):  
Cancer Risk ◽  
Molecular Basis ◽  
Ribosomal Proteins ◽  
Ribosome Biogenesis ◽  
Molecular Mechanisms ◽  
Cancer Susceptibility ◽  
Cancer Therapeutics ◽  
Diverse Range ◽  
Multiple Tumor ◽  
Recent Advances

AbstractRibosome biogenesis and protein synthesis are fundamental rate-limiting steps for cell growth and proliferation. The ribosomal proteins (RPs), comprising the structural parts of the ribosome, are essential for ribosome assembly and function. In addition to their canonical ribosomal functions, multiple RPs have extra-ribosomal functions including activation of p53-dependent or p53-independent pathways in response to stress, resulting in cell cycle arrest and apoptosis. Defects in ribosome biogenesis, translation, and the functions of individual RPs, including mutations in RPs have been linked to a diverse range of human congenital disorders termed ribosomopathies. Ribosomopathies are characterized by tissue-specific phenotypic abnormalities and higher cancer risk later in life. Recent discoveries of somatic mutations in RPs in multiple tumor types reinforce the connections between ribosomal defects and cancer. In this article, we review the most recent advances in understanding the molecular consequences of RP mutations and ribosomal defects in ribosomopathies and cancer. We particularly discuss the molecular basis of the transition from hypo- to hyper-proliferation in ribosomopathies with elevated cancer risk, a paradox termed “Dameshek’s riddle.” Furthermore, we review the current treatments for ribosomopathies and prospective therapies targeting ribosomal defects. We also highlight recent advances in ribosome stress-based cancer therapeutics. Importantly, insights into the mechanisms of resistance to therapies targeting ribosome biogenesis bring new perspectives into the molecular basis of cancer susceptibility in ribosomopathies and new clinical implications for cancer therapy.

Sign in / Sign up

Export Citation Format

Share Document